Physician profile
Mark Melden
NPI 1982653135
$9,722.17
in general payments reported to CMS, 2019-2025
32 companies · $2,500 in 2025
The $2,500 reported for 2025 was more than what 91% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,003 · 2020: $1,003 · 2021: $1,145 · 2022: $816 · 2023: $997 · 2024: $1,259 · 2025: $2,500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,560 · Education: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,560.11 |
| Education | $194.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,237.43 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $878.94 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $747.87 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $695.57 | 2019-2025 | Invega Sustenna, Spravato |
| Lundbeck LLC | $634.61 | 2019-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $628.08 | 2019-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $617.28 | 2019-2025 | Aristada, Lybalvi |
| Takeda Pharmaceuticals U.S.A., INC. | $587.83 | 2019-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $521.04 | 2021-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $502.18 | 2019-2025 | Ingrezza |
| Allergan, INC. | $464.04 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $274.34 | 2024-2025 | Cobenfy |
| Indivior INC. | $250.79 | 2019-2025 | Sublocade, Perseris |
| Corium, LLC | $239.89 | 2021-2024 | Azstarys |
| Supernus Pharmaceuticals, INC. | $224.74 | 2021-2025 | Qelbree, Qelbree |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $223.55 | 2019-2022 | |
| Axsome Therapeutics, INC. | $222.73 | 2022-2025 | Auvelity |
| Bausch Health US, LLC | $139.35 | 2021-2024 | Aplenzin, Wellbutrin |
| Ironshore Pharmaceuticals INC. | $81.34 | 2019-2020 | |
| Shire North American Group INC | $80.49 | 2019 | |
| Merck Sharp & Dohme LLC | $68.72 | 2020-2022 | |
| Collegium Pharmaceutical, INC. | $56.06 | 2025 | Jornay Pm |
| Biogen, INC. | $55.31 | 2025 | Zurzuvae |
| Jazz Pharmaceuticals INC. | $53.59 | 2019-2020 | |
| Almatica Pharma LLC | $48.94 | 2022-2025 | Loreev Xr |
| Neos Therapeutics, Lp | $38.28 | 2019-2025 | Adzenys Xr-Odt |
| Avanir Pharmaceuticals, INC. | $33.33 | 2019-2021 | |
| Boston Scientific Corporation | $27.99 | 2019 | |
| Lilly USA, LLC | $25.77 | 2025 | Mounjaro, Zepbound |
| Alfasigma USA, INC. | $22.39 | 2020 | |
| Tris Pharma INC | $21.64 | 2019 | |
| Vertical Pharmaceuticals, LLC | $18.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Melden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.